Variant Gene Disease Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs121913529
rs121913529
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0346647
Disease:
Malignant neoplasm of pancreas
0.050 GeneticVariation BEFREE Importantly, FGTI-2734 inhibited the growth of xenografts derived from four patients with pancreatic cancer with mutant KRAS (2 G12D and 2 G12V) tumors. 31227505 2019
dbSNP: rs121913529
rs121913529
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0346647
Disease:
Malignant neoplasm of pancreas
0.050 GeneticVariation BEFREE KRAS G12D point mutation plays an important role in the incidence of non-small-cell lung cancer (NSCLC) as well as colorectal cancer, pancreatic cancer and breast cancer. 30876538 2019
dbSNP: rs121913529
rs121913529
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0346647
Disease:
Malignant neoplasm of pancreas
0.050 GeneticVariation BEFREE The dominant oncogenic mutations of KRAS are single amino acid substitutions at codon 12, in particular G12D and G12V present in 60% to 70% of pancreatic cancers and 20% to 30% of colorectal cancers. 26701267 2016
dbSNP: rs121913529
rs121913529
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0346647
Disease:
Malignant neoplasm of pancreas
0.050 GeneticVariation BEFREE Oncogene-directed increased expression of Nrf2 is a new mechanism for the activation of the Nrf2 antioxidant program, and is evident in primary cells and tissues of mice expressing K-Ras(G12D) and B-Raf(V619E), and in human pancreatic cancer. 21734707 2011
dbSNP: rs121913529
rs121913529
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0346647
Disease:
Malignant neoplasm of pancreas
0.050 GeneticVariation BEFREE We find that physiological levels of Kras(G12D) induce ductal lesions that recapitulate the full spectrum of human pancreatic intraepithelial neoplasias (PanINs), putative precursors to invasive pancreatic cancer. 14706336 2003
dbSNP: rs121913530
rs121913530
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0346647
Disease:
Malignant neoplasm of pancreas
0.030 GeneticVariation BEFREE This study suggests that the combination of RAF and CDK4/6 inhibitors might be a novel treatment strategy for KRAS G12R mutant pancreatic cancer. 30271501 2018
dbSNP: rs121913530
rs121913530
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0346647
Disease:
Malignant neoplasm of pancreas
0.030 GeneticVariation BEFREE These effects were tested on MiaPaCa-2 human pancreatic cancer cells carrying a K-Ras activating mutation (G12C) after exposure to individual statins (20 μM). 29262834 2017
dbSNP: rs121913530
rs121913530
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0346647
Disease:
Malignant neoplasm of pancreas
0.030 GeneticVariation BEFREE Presence of the KRAS G12C mutation had 96% specificity and positive predictive value for lung adenocarcinoma, whereas G12R was 99% specific for pancreatic cancer with a positive predictive value of 86%. 23887294 2014
dbSNP: rs121913527
rs121913527
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0346647
Disease:
Malignant neoplasm of pancreas
0.010 GeneticVariation BEFREE Among fish injected with one of five KRAS mutations reported in other tumor types but not in human pancreatic cancer, 2/79 (2.5%) developed pancreatic tumors, with both tumors arising in fish injected with A146T. 25065594 2015